Here's Why Puma Biotechnology Tanked 37.3% in November

Shares of Puma Biotechnology, Inc. (NASDAQ: PBYI), a biotechnology company in the middle of its first new drug launch, fell 37.3% in November, according to data from S&P Global Market Intelligence. Sales of Nerlynx appear to be leveling off before getting anywhere near pre-launch expectations.